Literature DB >> 32109188

Open Fractures: Are We Still Treating the Same Types of Infections?

Jack D Sudduth1, James A Moss2, Clay A Spitler1, Vuong-Lam H Pham1, LaRita C Jones1, James Turner Brown1, Patrick F Bergin1.   

Abstract

Background: To analyze the rate of methicillin-resistant Staphylococcus aureus (MRSA), gram-negative, and polymicrobial infections in open fractures, measure the efficacy of the current open fracture antibiotic regimen against these infections, identify the most effective agent(s) to cover these infections, and analyze risk factors for infection.
Methods: We examined retrospectively 451 patients with open fractures from January 2008 to December 2012 who were treated at our facility. Positive cultures during surgical debridement after wound closure defined an infection. Infecting organisms and their antibiotic sensitivities were identified through microbiology culture reports. Rates of MRSA, gram-negative, and polymicrobial infections were determined. The efficacy of the current regimen (cefazolin and gentamicin) was calculated against gram-positive and gram-negative organisms. Efficacy profiles against infectious organisms were calculated for all commonly tested antibiotics. Patient factors, injury characteristics, and treatment options were analyzed to determine risk factors for infection.
Results: Ninety patients (20%) were identified as infected at surgical debridement. Of those 90, 21 (23.3%) were diagnosed with MRSA, 56 (62.2%) were found to have a gram-negative infection, and 46 (51.1%) had polymicrobial infections. Cephalosporins and β-lactam agents had a 59.2% efficacy rate against gram-positive bacteria and gentamicin showed a 94% sensitivity rate against gram-negative bacteria. Vancomycin (95.8% sensitivity) demonstrated the highest sensitivity for all gram-positive organisms. Amikacin (98.8% sensitivity), meropenem (96.3% sensitivity), and gentamicin (94.2% sensitivity) demonstrated excellent efficacy for all gram-negative organisms. Immuno-compromised status and Gustilo-Anderson type were the only independently predictive risk factors for infection in a multivariable model. Conclusions: Based on this analysis, the rate of MRSA, gram-negative, and polymicrobial infections in open fractures is high and increasing compared with historical cohorts. With the sensitivity of early generation cephalosporins being relatively poor against gram-positive organisms, the present antibiotic regimen for open, long-bone fractures may need to be reconsidered with these emerging trends.

Entities:  

Keywords:  MRSA; antibiotic prophylaxis; gram-negative; infection; open fractures; polymicrobial; risk factors

Year:  2020        PMID: 32109188     DOI: 10.1089/sur.2019.140

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  3 in total

1.  Tibial bone and soft-tissue concentrations following combination therapy with vancomycin and meropenem - evaluated by microdialysis in a porcine model : should patients with open fractures have higher doses of antibiotics?

Authors:  Sofus Ørbæk Vittrup; Pelle Hanberg; Martin Bruun Knudsen; Sara Kousgaard Tøstesen; Josephine Olsen Kipp; Jakob Hansen; Nis Pedersen Jørgensen; Maiken Stilling; Mats Bue
Journal:  Bone Joint Res       Date:  2022-02       Impact factor: 5.853

2.  Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Femur Osteomyelitis-A Case Report.

Authors:  Karlis Racenis; Dace Rezevska; Monta Madelane; Ervins Lavrinovics; Sarah Djebara; Aivars Petersons; Juta Kroica
Journal:  Front Med (Lausanne)       Date:  2022-04-25

3.  Pseudomonas aeruginosa Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in France.

Authors:  Matteo Cerioli; Cécile Batailler; Anne Conrad; Sandrine Roux; Thomas Perpoint; Agathe Becker; Claire Triffault-Fillit; Sebastien Lustig; Michel-Henri Fessy; Frederic Laurent; Florent Valour; Christian Chidiac; Tristan Ferry
Journal:  Front Med (Lausanne)       Date:  2020-10-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.